Loading…
Rigel Pharmaceuticals, Inc. is projected to rise to $53.34 by 2027, a +45% move from its current price of $36.81. RIGL is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $36.01 | $36.82 | $37.65 | +0.03% |
| Aug 3 | $35.70 | $36.83 | $38.00 | +0.06% |
| Aug 4 | $35.46 | $36.84 | $38.28 | +0.09% |
| Aug 5 | $35.26 | $36.85 | $38.52 | +0.12% |
| Aug 6 | $35.08 | $36.86 | $38.74 | +0.15% |
| Aug 7 | $34.93 | $36.88 | $38.93 | +0.18% |
| Aug 8 | $34.79 | $36.89 | $39.11 | +0.21% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $34.79 | $36.89 | $39.11 | +0.21% |
| Week 2 | $34.02 | $36.96 | $40.16 | +0.41% |
| Week 3 | $33.46 | $37.04 | $41.00 | +0.62% |
| Week 4 | $33.01 | $37.12 | $41.73 | +0.83% |
| Week 5 | $32.62 | $37.19 | $42.40 | +1.04% |
| Week 6 | $32.28 | $37.27 | $43.02 | +1.25% |
| Week 7 | $31.98 | $37.35 | $43.61 | +1.46% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Rigel Pharmaceuticals, Inc. is a biotechnology company that develops therapies to enhance the lives of patients with hematologic disorders and cancer in the United States.
The company was incorporated in 1996 and is headquartered in South San Francisco, California.
Its portfolio includes TAVALISSE for adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation.
Rigel Pharmaceuticals, Inc. (RIGL) sits in the Healthcare category and currently trades at $39.31 with a market cap of $727.32M and a rank of 2747.
The forecast outlines a rising price trajectory with the average price moving higher across the years, beginning with a 2026 avg of $39.31 and extending to a 2050 avg of $862.78 and a 2050 max of $1,485.20, signaling substantial long-term upside despite near-term uncertainty.
In 2026, the average is $39.31 with a neutral sentiment; in 2027 the average rises to $57.98 (bullish) and in 2028 to $74.17 (bullish). By 2030 the avg is $108.13 (bullish) and the 2040 and 2050 forecasts rise to $391.87 and $862.78 respectively, with the 2050 max at $1,485.20 and a long-run bullish signal implied by the numbers.
A major floor 30.1% below — a decisive break under it would weaken the trend.
The nearest floor, 10.6% below — buyers have tended to step in here.
The nearest ceiling, 18.9% above — a clean break opens room to run.
A major ceiling 32.2% above — clearing it would confirm fresh momentum.
Key RIGL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RIGL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $37.97 | Sell | $37.78 | Sell |
| MA 10 | $38.02 | Sell | $38.26 | Sell |
| MA 20 | $39.90 | Sell | $38.42 | Sell |
| MA 50 | $35.64 | Buy | $36.45 | Buy |
| MA 100 | $32.10 | Buy | $34.74 | Buy |
| MA 200 | $34.97 | Buy | $33.16 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 44.20 | Neutral |
| Stoch RSI (14) | 3.81 | Buy |
| CCI (20) | -109.30 | Sell |
| Williams %R (14) | -98.58 | Info |
| MACD (12,26,9) | -0.61 | Sell |
| ROC (12) | -10.61 | Sell |
| Bollinger %B (20,2) | 0.14 | Neutral |
| Stochastic %K (14) | 1.42 | Buy |
| TRIX (15) | 0.38 | Buy |
| Awesome (5,34) | -0.32 | Sell |
| Ultimate (7,14,28) | 39.02 | Neutral |
| Momentum (10) | -3.73 | Sell |
| Aroon Osc (25) | -44.00 | Sell |
| Hull MA (9) | 38.26 | Sell |
| ADX (14) | 23.24 | Sell |
| ATR (14) | 0.82 | Info |
The 30-day technical picture is bullish. RSI(14) is 50, while the moving averages show SMA50 at $34.25 and SMA200 at $34.60. Support sits at $30.08 and resistance at $43.76, framing a 30-day range of $33.94 to $45.53.
Overall, near-term volatility is reflected in an annualized volatility of 40%, with the price oscillating within a relatively tight band around the current level.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $25.44 | $36.81 | $46.70 | 0% | Neutral | |
| $43.27 | $53.34 | $69.05 | +45% | Bullish | |
| $54.31 | $68.48 | $91.47 | +86% | Bullish | |
| $64.63 | $83.00 | $113.61 | +125% | Bullish | |
| $76.33 | $99.62 | $139.21 | +171% | Bullish | |
| $81.74 | $108.27 | $154.06 | +194% | Bullish | |
| $94.54 | $126.93 | $183.56 | +245% | Bullish | |
| $108.84 | $147.99 | $217.20 | +302% | Bullish | |
| $127.13 | $174.95 | $260.27 | +375% | Bullish | |
| $157.40 | $219.11 | $330.11 | +495% | Bullish | |
| $242.57 | $355.48 | $564.80 | +866% | Bullish | |
| $484.16 | $773.61 | $1,329.13 | +20.0x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $25.44 | $36.81 | $43.68 | +0.00% |
| September 2026 | $31.89 | $37.53 | $45.26 | +1.95% |
| October 2026 | $31.96 | $37.81 | $46.00 | +0.76% |
| November 2026 | $31.28 | $37.17 | $45.54 | -1.70% |
| December 2026 | $31.74 | $37.88 | $46.70 | +1.91% |
Click any year to see its month-by-month RIGL forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Rigel Pharmaceuticals, Inc.'s 2026 outlook centres on $36.81, within a $25.44 to $46.70 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, RIGL could reach as high as $69.05, with a base case around $53.34 and support toward $43.27 — roughly +45% from $36.81. Momentum favours further upside here.
Expect RIGL to range from $54.31 to $91.47 through 2028. The $68.48 average target implies a +86% move from current prices. That is up +28% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The RIGL price prediction for 2029 points to an average of $83.00 (low $64.63, high $113.61) — a potential gain of +125% on today's $36.81. Momentum favours further upside here.
In 2030, RIGL is projected to trade between $76.33 and $139.21, averaging $99.62 — a potential gain of +171% from today's $36.81. That is up +20% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Rigel Pharmaceuticals, Inc.'s 2031 outlook centres on $108.27, within a $81.74 to $154.06 range. That is up +9% on the projected 2030 average. That marks a +194% change versus current levels. Momentum favours further upside here.
By 2032, RIGL could reach as high as $183.56, with a base case around $126.93 and support toward $94.54 — roughly +245% from $36.81. Buyers look set to stay in control over this stretch.
Expect RIGL to range from $108.84 to $217.20 through 2033. The $147.99 average target implies a +302% move from current prices. That is up +17% on the projected 2032 average. Momentum favours further upside here.
The RIGL price prediction for 2034 points to an average of $174.95 (low $127.13, high $260.27) — a potential gain of +375% on today's $36.81. Buyers look set to stay in control over this stretch.
In 2035, RIGL is projected to trade between $157.40 and $330.11, averaging $219.11 — a potential gain of +495% from today's $36.81. That is up +25% on the projected 2034 average. Momentum favours further upside here.
Rigel Pharmaceuticals, Inc.'s 2040 outlook centres on $355.48, within a $242.57 to $564.80 range. That is up +62% on the projected 2035 average. That marks a +866% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, RIGL could reach as high as $1,329.13, with a base case around $773.61 and support toward $484.16 — roughly +20.0x from $36.81. Momentum favours further upside here.
Investing $1,000 in RIGL today (≈ 27.166531 RIGL) could be worth
$21,016.42
+$20,016.42 (+2002%) by 2050 · US Dollar
Based on the average projected RIGL price of $773.61 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RIGLwould be worth at today's price.
$1,000 invested in RIGL on Jul 31, 2025 (≈ 47.483382 RIGL) would be worth
$1,747.86
+$747.86 (+74.8%) today · 1.75× · US Dollar
Based on a RIGL entry price of $21.06 vs. today's $36.81.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $36.74 | $1,001.91 | +0.2% |
| 1 month ago | $38.29 | $961.35 | -3.9% |
| 3 months ago | $29.4 | $1,252.04 | +25.2% |
| 6 months ago | $36.01 | $1,022.22 | +2.2% |
| 1 year ago | $21.06 | $1,747.86 | +74.8% |
| All time (5.0y) ago | $40.2 | $915.67 | -8.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RIGL forecast.
Our base-case forecast reaches $74.00 around 2029.
Implied market cap at $74.00: $1.37B
The multi-year forecast shows a clear bullish trajectory after the near term. For 2026 the min is $25.44, the avg is $39.31, and the max is $50.89, with a 0 ROI and NEUTRAL sentiment. In 2027 the avg climbs to $57.98 and the max to $75.17, yielding a 47.5 ROI and a BULLISH sentiment.
The 2028 and 2029 outlooks strengthen to $74.17 (avg) and $99.20 (max) for 2028 (ROI 88.7, BULLISH) and $90.37 (avg) and $123.88 (max) for 2029 (ROI 129.9, BULLISH).
By 2030 the forecast shows an avg of $108.13 with a max of $151.31 and a 175.1 ROI, continuing the BULLISH sentiment. The path extends through 2031 ($117.49 avg, $167.42 max, ROI 198.9), 2032 ($139.19 avg, $201.59 max, ROI 254.1), and 2033 ($161.99 avg, $238.10 max, ROI 312.1), into 2034 ($192.11 avg, $286.24 max, ROI 388.7) and 2035 ($242.79 avg, $366.36 max, ROI 517.6).
Longer term, 2040 shows an avg of $391.87 with a max of $623.69 (ROI 896.9, BULLISH), and 2050 projects an avg of $862.78 with a max of $1,485.20 (ROI 2094.8, BULLISH). These figures reflect a continued bullish bias with meaningful upside potential but also inherent uncertainty and variability over extended horizons.
Tap a question to reveal the answer.
The forecast for 2030 shows an avg price of $108.13 and a max of $151.31, with ROI 175.1 and a BULLISH sentiment.
From 2027 onward the forecast is bullish with rising averages (e.g., $57.98 in 2027, $74.17 in 2028, $90.37 in 2029, $108.13 in 2030) and ROI reaching 175.1 by 2030 and up to 2094.8 by 2050, though 2026 starts neutral.
Yes. The 2030 max is $151.31, with 2030 avg $108.13 and 2030 min $82.75.
Sentiment is BULLISH. RSI(14) is 50. SMA50 is $34.25 and SMA200 is $34.60. Support is $30.08 and resistance is $43.76. The 30-day range is $33.94 to $45.53, with volatility around 40%.
Current price is $39.31. Market cap is $727.32M. Rank is 2747.
Rigel Pharmaceuticals, Inc. Community Discussion
0Share your Rigel Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.